FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981266251> ?p ?o ?g. }

• W1981266251 endingPage "585" @default.
• W1981266251 startingPage "579" @default.
• W1981266251 abstract "A marked antitumour efficacy is currently obtained by oxaliplatin (LOHP)-fluorouracil (FU)-folinic acid (FA) combination and by CPT11-FU-FA combination. Logically, the triple association LOHP, CPT11 and FUFA will be soon tested in cancer patients. The aim of the present study was to compare two schedules combining SN38 (the active metabolite of CPT11, irinotecan) with FU-FA and LOHP. The two schedules differed by the SN38 position. The relative contribution of each drug in the resulting global cytotoxicity was evaluated. Two human colon cancer cell lines were used (WIDR and SW620 both p53 mutated). LOHP plus FA were applied for 2 h, just before a 48 h FU exposure. The SN38 sequence was applied for 24 h, starting either 48 h before LOHP-FA (schedule A), or just after LOHP-FA exposure (schedule B). Cytotoxicity was assessed by the 3-(4,5-demethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) test and drug interactions were analysed according to the Chou and Talalay method, based on the computation of a combination index (CI). The SN38 position significantly induces a shift from additivity-antagonism when SN38 was applied after LOHP, towards additivity-synergism when SN38 was applied first (P = 0.03). The relative contribution (RC) of each drug in the overall cytotoxicity of the triple combination was defined as the drug concentration giving 50% cell lethality (IC(50)) of the double association without that drug divided by the IC(50)of the triple association. Whatever the SN38 position, the larger contribution was made by LOHP (median RC = 2.4) and the smaller by SN38 (median RC = 1.1). In addition, the contribution of FUFA was improved when SN38 was applied first (median RC = 2.2) as compared to the opposite schedule (median RC = 1.2). Results were in agreement between the two explored cell lines. The present data should be taken into account when establishing the rationale of future trials combining CPT11, LOHP and FU-FA." @default.
• W1981266251 created "2016-06-24" @default.
• W1981266251 creator A5030092454 @default.
• W1981266251 creator A5047469475 @default.
• W1981266251 creator A5055514871 @default.
• W1981266251 creator A5075050232 @default.
• W1981266251 creator A5081180030 @default.
• W1981266251 creator A5090050048 @default.
• W1981266251 date "2001-01-01" @default.
• W1981266251 modified "2023-10-18" @default.
• W1981266251 title "Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines" @default.
• W1981266251 cites W1864471800 @default.
• W1981266251 cites W1911437776 @default.
• W1981266251 cites W1929570960 @default.
• W1981266251 cites W1958660371 @default.
• W1981266251 cites W1977379434 @default.
• W1981266251 cites W2006824814 @default.
• W1981266251 cites W2015829835 @default.
• W1981266251 cites W2028547579 @default.
• W1981266251 cites W2032146688 @default.
• W1981266251 cites W2036409540 @default.
• W1981266251 cites W2048950936 @default.
• W1981266251 cites W2066312401 @default.
• W1981266251 cites W2069733373 @default.
• W1981266251 cites W2077945404 @default.
• W1981266251 cites W2080106203 @default.
• W1981266251 cites W2081048612 @default.
• W1981266251 cites W2096122707 @default.
• W1981266251 cites W2116603453 @default.
• W1981266251 cites W2119112791 @default.
• W1981266251 cites W2121368761 @default.
• W1981266251 cites W2122731269 @default.
• W1981266251 cites W2128447158 @default.
• W1981266251 cites W2133289060 @default.
• W1981266251 cites W2140927361 @default.
• W1981266251 cites W2171465492 @default.
• W1981266251 cites W2314927739 @default.
• W1981266251 cites W2411672502 @default.
• W1981266251 cites W259227149 @default.
• W1981266251 doi "https://doi.org/10.1054/bjoc.2000.1600" @default.
• W1981266251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2363774" @default.
• W1981266251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11207057" @default.
• W1981266251 hasPublicationYear "2001" @default.
• W1981266251 type Work @default.
• W1981266251 sameAs 1981266251 @default.
• W1981266251 citedByCount "45" @default.
• W1981266251 countsByYear W19812662512013 @default.
• W1981266251 countsByYear W19812662512014 @default.
• W1981266251 countsByYear W19812662512015 @default.
• W1981266251 countsByYear W19812662512016 @default.
• W1981266251 countsByYear W19812662512017 @default.
• W1981266251 countsByYear W19812662512018 @default.
• W1981266251 countsByYear W19812662512020 @default.
• W1981266251 countsByYear W19812662512021 @default.
• W1981266251 countsByYear W19812662512023 @default.
• W1981266251 crossrefType "journal-article" @default.
• W1981266251 hasAuthorship W1981266251A5030092454 @default.
• W1981266251 hasAuthorship W1981266251A5047469475 @default.
• W1981266251 hasAuthorship W1981266251A5055514871 @default.
• W1981266251 hasAuthorship W1981266251A5075050232 @default.
• W1981266251 hasAuthorship W1981266251A5081180030 @default.
• W1981266251 hasAuthorship W1981266251A5090050048 @default.
• W1981266251 hasBestOaLocation W19812662511 @default.
• W1981266251 hasConcept C109316439 @default.
• W1981266251 hasConcept C121608353 @default.
• W1981266251 hasConcept C126322002 @default.
• W1981266251 hasConcept C185592680 @default.
• W1981266251 hasConcept C202751555 @default.
• W1981266251 hasConcept C2776262904 @default.
• W1981266251 hasConcept C2778305200 @default.
• W1981266251 hasConcept C2779804826 @default.
• W1981266251 hasConcept C2780259306 @default.
• W1981266251 hasConcept C2780962732 @default.
• W1981266251 hasConcept C502942594 @default.
• W1981266251 hasConcept C526805850 @default.
• W1981266251 hasConcept C552990157 @default.
• W1981266251 hasConcept C55493867 @default.
• W1981266251 hasConcept C64927066 @default.
• W1981266251 hasConcept C71924100 @default.
• W1981266251 hasConcept C98274493 @default.
• W1981266251 hasConceptScore W1981266251C109316439 @default.
• W1981266251 hasConceptScore W1981266251C121608353 @default.
• W1981266251 hasConceptScore W1981266251C126322002 @default.
• W1981266251 hasConceptScore W1981266251C185592680 @default.
• W1981266251 hasConceptScore W1981266251C202751555 @default.
• W1981266251 hasConceptScore W1981266251C2776262904 @default.
• W1981266251 hasConceptScore W1981266251C2778305200 @default.
• W1981266251 hasConceptScore W1981266251C2779804826 @default.
• W1981266251 hasConceptScore W1981266251C2780259306 @default.
• W1981266251 hasConceptScore W1981266251C2780962732 @default.
• W1981266251 hasConceptScore W1981266251C502942594 @default.
• W1981266251 hasConceptScore W1981266251C526805850 @default.
• W1981266251 hasConceptScore W1981266251C552990157 @default.
• W1981266251 hasConceptScore W1981266251C55493867 @default.
• W1981266251 hasConceptScore W1981266251C64927066 @default.
• W1981266251 hasConceptScore W1981266251C71924100 @default.
• W1981266251 hasConceptScore W1981266251C98274493 @default.
• W1981266251 hasIssue "4" @default.

• next